RAPT Therapeutics (RAPT) Cash from Investing Activities (2020 - 2024)
Historic Cash from Investing Activities for Therapeutics (RAPT) over the last 5 years, with Q4 2024 value amounting to -$843000.0.
- Therapeutics' Cash from Investing Activities fell 10408.45% to -$843000.0 in Q4 2024 from the same period last year, while for Dec 2024 it was $52.7 million, marking a year-over-year decrease of 4938.97%. This contributed to the annual value of $52.7 million for FY2024, which is 4938.97% down from last year.
- Per Therapeutics' latest filing, its Cash from Investing Activities stood at -$843000.0 for Q4 2024, which was down 10408.45% from $18.4 million recorded in Q3 2024.
- In the past 5 years, Therapeutics' Cash from Investing Activities ranged from a high of $32.4 million in Q2 2023 and a low of -$63.7 million during Q2 2021
- Its 5-year average for Cash from Investing Activities is -$2.9 million, with a median of $6.7 million in 2020.
- As far as peak fluctuations go, Therapeutics' Cash from Investing Activities tumbled by 143716.98% in 2021, and later surged by 41016.45% in 2023.
- Therapeutics' Cash from Investing Activities (Quarter) stood at $15.5 million in 2020, then tumbled by 202.56% to -$15.9 million in 2021, then plummeted by 159.69% to -$41.3 million in 2022, then soared by 150.01% to $20.6 million in 2023, then plummeted by 104.08% to -$843000.0 in 2024.
- Its last three reported values are -$843000.0 in Q4 2024, $18.4 million for Q3 2024, and $19.2 million during Q2 2024.